Latest long-term debt for RADD: $160K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
AB US Research Advanced ETF posts a long-term debt of $160K as of June 2026. That compares with $290K in the prior-year period — down 44.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, AB US Research Advanced ETF's long-term debt was $290K. The latest reading is $160K — a 44.1% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
Long-Term Debt is one piece of AB US Research Advanced ETF's financial statement story. At $160K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for RADD's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; AB US Research Advanced ETF's other metric pages and overview cover the third.
Judging AB US Research Advanced ETF against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $160K here, then scan peer and history charts to see if the gap is persistent.